Godavari Biorefineries secures Chinese patent for anti-cancer molecule

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats

Cipla to invest in iCaltech to strengthen respiratory play

iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus

Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications

She was Group Chief Marketing Officer at CKA Birla Group in her last role

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

Fortis and Gleneagles India deepen collaboration to drive growth

Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US

Miltenyi Biotec and THSTI partner to launch CAR-T Cell and gene therapy training curriculum

This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.

Sun Pharma’s phase 3 Cclinical studies for Tildrakizumab 100 mg meet primary endpoint

The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D